ORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet

Similar documents
Rare Diseases: Challenges and Opportunities NIH Perspective

Comments about Rare diseases: Europe s challenge from the Public and Professional Policy Committee of the European Society for Human Genetics.

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University

Question 1: Better codification and classification of RD Yes, we agree. Question 2: Establishment of an inventory of RD Yes I agree.

Disease Specific Registries vs Product Registries

Orphan Medicinal Products

Understanding the impact of publications in specialist areas: focus on orphan drugs

Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy?

6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels

The Curative and Transformative Potential of Novel Therapies for Rare Diseases in the Age of Precision Medicine

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Clinical studies. BARBORA VLKOVÁ INSTITUTE OF MOLECULAR BIOMEDICINE

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

Genomics and SNOMED CT (the way ahead) Ian Green Customer Relations Lead, Europe and Clinical Engagement Business Manager

Recent Trends in Companion Diagnostic Test Development Partnerships

EU support for Health Research from FP6 to FP7

Orphan Designation System in Japan. 10, March 2014 Ministry of Health, Labour and Welfare

Novartis Response to the Commission Consultation. Rare Diseases: Europe s Challenge

Personalized. Health in Canada

consent. With the exception, such as impossible to obtain informed consent objectively or there is no risk of the clinical trial for subjects, the res

To Partner or Not to Partner:

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

QPS Neuropharmacology Overview

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

- OMICS IN PERSONALISED MEDICINE

Guide for National Scientific and Regulatory Advice

Guide to EU Clinical Trial Application Form

The Leader in AAV Gene Therapy. A Guide to AAV Gene Therapy for MPS I and II

EU Regulation Review: challenges and opportunities for industry

REIMAGINING DRUG DEVELOPMENT:

Meeting report series. Report of the 2nd Companies Constituent Committee Meeting

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Orphan Products and Drug Development 2015 MARLENE E. HAFFNER, MD MPH HAFFNER ASSOCIATES AS PRESENTED TO GLG SEPTEMBER 23RD, 2015

KPI Definition Comment Relates to Baseline Target

Personalised Medicine Regulatory Issues

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Stem Cell Research: Identifying emerging high priority policy issues

Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products (Therapeutic Products Fees Ordinance)

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Genomics in the NHS. Professor Sue Chief Scientific Officer for England

Engage with us on Twitter: #Molecule2Miracle

Genomics and personalised medicine

Regulatory Support to EU Research

The role of patients in clinical research

Type of Activity. Universal Activity Number L04-P

NETWORKING AND CUREACCELERATOR LIVE!

Clinical Trial Methods Course 2017 Trials in Rare Diseases. Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017

Genetic databases. Anna Sowińska-Seidler, MSc, PhD Department of Medical Genetics

Docket #: FDA-2018-D-3268

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

The Need for, and Application of, Natural History Data in Orphan Disease Medical Product Development

Importance of Research on Rare Diseases and Orphan Drugs

Course Agenda. Day One

While individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES

Milano, September 7 th 2016

Prosensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy

E-Rare: Era-Net for Research Programmes on Rare Diseases

Global registries for rare diseases: challenges and solutions

Idorsia Company Profile

NHS ENGLAND BOARD PAPER

To begin from the beginning

JP Morgan Healthcare Conference

- PRESS RELEASE April 6 th, 2007 PRESS RELEASE April 6 th, PRESS RELEASE -

Epiomic Segmentation Database......providing the depth of knowledge to better understand your patient population

Workshop 2 Getting involved in Research How can patient organizations trigger an EUfunded rare disease project?

Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS

The future of drug repurposing for rare diseases. Dr Rick Thomson CEO, Findacure

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Commission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03)

Innovative Medicines Initiative - the story so far

A. TRIAL IDENTIFICATION

Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective

BIOTECH IN FRANCE. key info in. points

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

CLINICAL TRIAL AUTHORIZATION APPLICATION FORM

Prosensa Therapeutics R&D in ultra-rare disease

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

Drug development and evaluation with small clinical Trials from the regulatory point of view

Question Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional

FINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts

HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?

The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels

The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation

University of California Center for Accelerated Innovation

Preparing For A New Era of Medical Product Development

Children s health and the environment

Biotech Patents in Europe

The contribution of the Central & Eastern European Genetic Network (CEEGN) towards prevention and treatment of genetic diseases

Fast Track Drug Development The Clinical (Caleidoscopic) Perspective

WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE

INTERNATIONAL SYMPOSIUM ON USHER SYNDROME

Nordic Common Strengths and Future Potential in the Field of Personalised Medicine

Unlocking protein production with translational read-through for rare genetic diseases. Investor Presentation February 2018

EUROPLAN NATIONAL CONFERENCES CONTENT GUIDELINES FOR WORKSHOP 3 / THEME 3 RESEARCH FOR RARE DISEASES

SPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium

Transcription:

ORPHANET s Services for Researchers Valérie THIBAUDEAU Database Manager Orphanet

Services for Researchers Needs Access classifications, genes Identify experts Collaborate Quickly recruit volunteers Establish partnerships Solutions Free-access list Database of experts Directory of current research projects Registration for clinical studies OrphanXchange

Indexing Rare Diseases Indexing clinical signs and symptoms OMIM # : catalogue of genes and genetic diseases ICD-10 code : international coding system of WHO MeSH : Medical Subject Heading genes, mode of inheritance age group of appearance, prevalence Access to other documentary resources Links to Medline for each rare disease Links to reference websites Links to a gene database: GenAtlas Key figures 5 500 diseases 1 125 diseases indexed with MeSH 1 600 diseases with links to Medline 5 205 links to other sites

List of Current Research Projects Genetic research Development of a new diagnostic protocol Gene mutation research Development of a new medical device Gene expression Development of a new vaccine Genotype/phenotype correlation Clinical trial of a new drug Physiopathology and model in vitro Clinical trial of a new diagnostic instrument Physiopathology and model in vivo Clinical trial of a new protocol Natural history Clinical trial of a vaccine Gene therapy Epidemiological studies Cell therapy Registries/ Observatories/ Cohorts Biomarkers Epidemiological studies Biological collections / resources Research in health sociology Preclinical development of a new drug Research in health economics Development of a new diagnostic Public Health instrument Key figures In Europe : 4 625 projects of which 13% are clinical trials

Collaboration in Data Collection Sources Voluntary submissions from professionals Research institutes and bodies Research networks Financing agencies Patient groups European Commission Validation Continuous updates Validations by professionals Scientific consultants in each country

Bimonthly Newsletters Key research findings New syndromes, genetic discoveries Calls for collaboration Calls for recruitment Scientific meetings and events

Free-access Electronic Journal Orphanet Journal of Rare Diseases Open publication for : clinical articles research articles methodological articles review articles negative results of clinical trials Key figures 51 articles published in 2006 20% highly accessed More than 10 000 visitors per month

A Tool for Project Development Partnership with LEEM and financial suppport of DG Recherche Identification of Drugs with Potential for Rare Diseases Previously Authorised for Another Indication What are the products? Statute of marketing: market authorization, interrupted production Clinical experience Biographical references Key figures 131 drugs with 215 potential rare disease indications

A Tool for Innovative Development Identification of Clinical Research Barriers Difficulties in: organisation of research following of clinical trials finding partnerships patient recruitment development of protocols funding for clinical trials identification of and collaboration with research centres administrative channels Identification of Products Under Development Diagnostic tools Monoclonal AC Oligonucleotides

A Database of Innovative Projects Database Research projects with potential indications for rare disease diagnosis or treatment Molecules with potential orphan indication License offers in France and Europe Networking Establishing relationships between academic research and industry

Users register with OrphanXchange Étape 1 Project search Projects with potential indications for rare disease diagnosis or treatement (129 projets) - new products - drugs with alternative indication www.orphanxchange.org Innovative Projectss Étape 2 Selection of projects by disease category by product type Étape 3 Request for contact with researcher or clinician Researchers/ clinicians

Networking Seeking contacts, both in and outside Europe Putting representatives in contact, organising meetings Establishing relationships between academic researchers and industry professionals Provides the opportunity to bring together biotechs and investors industry and clinical networks

OrphanXchange figures Website use 215 registered users 31 countries: Europe, USA, Japan 46% private sector: industry, biotech, investors 500 visits per month 113 contacts established Placement Pro-active go-between facilitating partnerships

Thank you for your attention